Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 70Neoplasms 47Carcinoma, Non-Small-Cell Lung 26Colorectal Neoplasms 20Neoplasm Metastasis 15Multiple Myeloma 14Thyroid Neoplasms 12Glioma 12Pancreatic Neoplasms 11Hematologic Neoplasms 10Thyroid Carcinoma, Anaplastic 9Brain Neoplasms 8Lung Neoplasms 7Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Neurofibromatosis 1 5Lymphoma 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Breast Neoplasms 5Astrocytoma 5Thyroid Cancer, Papillary 4Prostatic Neoplasms 4Neurofibroma, Plexiform 4Glioblastoma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uveal Melanoma 3Skin Neoplasms 3Recurrence 3

Interventions

Carboplatin 69Paclitaxel 47Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 36Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6ceritinib 5capmatinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Mastectomy, Segmental 5Cyclophosphamide 5tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma of Lung × trametinib × Clear all
NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
24 enrolled 8 charts
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔